Isolation and characterisation of Leishmania donovani protein antigens from urine of visceral leishmaniasis patients

PLoS One. 2020 Sep 14;15(9):e0238840. doi: 10.1371/journal.pone.0238840. eCollection 2020.

Abstract

Diagnosis of visceral leishmaniasis (VL) relies on invasive and risky aspirate procedures, and confirmation of cure after treatment is unreliable. Detection of Leishmania donovani antigens in urine has the potential to provide both a non-invasive diagnostic and a test of cure. We searched for L. donovani antigens in urine of VL patients from India and Sudan to contribute to the development of urine antigen capture immunoassays. VL urine samples were incubated with immobilised anti-L. donovani polyclonal antibodies and captured material was eluted. Sudanese eluted material and concentrated VL urine were analysed by western blot. Immunocaptured and immunoreactive material from Indian and Sudanese urine was submitted to mass spectrometry for protein identification. We identified six L. donovani proteins from VL urine. Named proteins were 40S ribosomal protein S9, kinases, and others were hypothetical. Thirty-three epitope regions were predicted with high specificity in the 6 proteins. Of these, 20 were highly specific to Leishmania spp. and are highly suitable for raising antibodies for the subsequent development of an antigen capture assay. We present all the identified proteins and analysed epitope regions in full so that they may contribute to the development of non-invasive immunoassays for this deadly disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Protozoan / immunology
  • Antibodies, Protozoan / isolation & purification
  • Antibodies, Protozoan / urine*
  • Antigens, Protozoan / immunology
  • Antigens, Protozoan / isolation & purification
  • Antigens, Protozoan / urine*
  • Case-Control Studies
  • Humans
  • India / epidemiology
  • Leishmania donovani / immunology*
  • Leishmania donovani / isolation & purification
  • Leishmaniasis, Visceral / diagnosis*
  • Leishmaniasis, Visceral / epidemiology
  • Leishmaniasis, Visceral / urine
  • Protozoan Proteins / immunology
  • Protozoan Proteins / isolation & purification
  • Protozoan Proteins / urine*

Substances

  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Protozoan Proteins

Grants and funding

TM was funded by the Sir Halley Stewart Trust (http://www.sirhalleystewart.org.uk/). The views expressed within this report are those of the authors and not necessarily those of the Trust. TM was additionally supported by the John Henry Memorial Fund (UK Charity number: 1118007). This work was part of the NIDIAG network research partnership supported by the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme (Grant agreement no. 260260, https://cordis.europa.eu/project/id/260260). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.